PDF(Pubmed)
Abstract：
It is well established that people with diabetes are at an increased risk of cardiovascular disease compared with those without diabetes. Although the protective role of aspirin in secondary prevention is well documented, its role in primary prevention of cardiovascular disease in people with diabetes, after the results of major clinical trials and meta-analyses, is unclear. The observed discrepancies might be explained in part in terms of the differences between the background cardiovascular risks, follow-up periods, age and gender of the study populations. Recently, the results of the ASCEND trial in people with diabetes documented the cardiovascular benefit of aspirin for primary prevention, but with an increased risk of bleeding that might outweigh the observed cardiovascular benefit. Therefore, current guidelines recommend its use for primary prevention in people with and without diabetes under specific circumstances. The purpose of the present review is to summarize the existing literature data regarding the place that aspirin has in primary prevention of cardiovascular disease in people with diabetes.
摘要：
众所周知，与没有糖尿病的人相比，糖尿病患者患心血管疾病的风险增加。虽然阿司匹林在二级预防中的保护作用是有据可查的，它在糖尿病患者心血管疾病一级预防中的作用，在主要临床试验和荟萃分析的结果之后，不清楚。观察到的差异可能部分解释为背景心血管风险之间的差异，后续期,研究人群的年龄和性别。最近,ASCEND在糖尿病患者中的试验结果证明了阿司匹林用于一级预防的心血管益处，但是出血风险增加，可能超过观察到的心血管益处。因此,目前的指南建议在特定情况下，将其用于糖尿病患者和非糖尿病患者的一级预防。本综述的目的是总结有关阿司匹林在糖尿病患者心血管疾病一级预防中的作用的现有文献资料。
